Analysis of Opportunities and Countermeasures of Drug Technology Transfer in China
10.6039/j.issn.1001-0408.2017.19.01
- VernacularTitle:我国药品技术转让时机及应对策略分析
- Author:
Yue HAN
;
Lanru LIU
;
Hong ZHU
;
Shuang XING
- Keywords:
Drug technology transfer;
Drug registration approval;
Opportunities for drug transfer;
Countermeasures for drug transfer;
New drugs;
Generic drugs;
Imported drugs
- From:
China Pharmacy
2017;28(19):2593-2596
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the risk,advantages and disadvantages and countermeasures of new drugs,generic drugs and imported drugs in different transfer opportunities,and to provide basis for improvement of development strategy for phar-maceutical enterprises. METHODS:The analysis was done in accordance with relevant regulations on transferable projects in the process of applying for registrations of new drugs,generic drugs and imported drugs. The transfer period and risk were explored and countermeasures were put forward. RESULTS & CONCLUSIONS:Transferable projects included intellectual property rights (patents,patent application,technical secrets,application information,non-disclosed data,etc.)and ownership rights(clinical tri-al approvals,new drug certificates,drug approval number,pharmaceutical product registration certificates,imported product regis-tration certificates,etc.)in the process of applying for registrations. There are 4 opportunities for drug technology transfer,opportu-nity 1 is before applying clinical trial approvals after the completion of non-clinical research such as pharmacology,toxicology;op-portunity 2 is ahead of clinical trial after the acquirement of clinical trial approvals;opportunity 3 is new drug technology transfer;opportunity 4 is production technology transfer. The new drugs have 4 transfer opportunities,generic drugs and imported drugs can transfer in opportunity 1,2,4. Different transfer opportunities present different risks and profits. The risk gradually decreases with the further promotion of drug registration process,while the innovation decreases at the same time. Pharmaceutical enterprises should combine with the policy,market and their own features to select a suitable transfer period.
